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Docetaxel-based chemotherapy appears to have considerable promise in advanced gastric cancer. In phase II
studies of single agent docetaxel, response rates (RRs) of 17% to 24% have been achieved in previously
untreated patients. Importantly, RRs of 20% to 22% are seen in second-line treatment. Work by a Swiss and
Italian collaborative group has shown that the combination of docetaxel 85 mg/m2 with cisplatin 75 mg/m2
every 3 weeks is quite active, achieving an RR of 55% and median survival of 9 months. Hematotoxicity was the
main adverse event but was manageable. In other respects the docetaxel/cisplatin doublet (TC) was relatively
well tolerated. The same group demonstrated that continuous infusion of 5-fluorouracil (5-FU) 300 mg/m2 can
be given on 2 weeks out of 3 to patients receiving TC. The addition of 5-FU, by this schedule, to TC (TCF) does
not increase hematological toxicity, and does not compromise the tolerability of TC. An overall RR of 55% has
been reported with TCF. A randomized phase II comparison of TC or TCF versus an ECF (epirubicin/cisplatin/
5-FU) control arm is ongoing and should lead to a randomized phase III trial comparing TC or TCF with ECF.
In an already completed international randomized phase II comparison of TC versus TCF (TAX-325), the three-
drug combination proved significantly more active (RR 54% versus 32% with TC, among patients treated per
protocol). Time to progression was also longer for TCF. Gastrointestinal (but not hematological) toxicity was
less with TC. TCF was chosen for ongoing phase III comparison against a control 5-FU/cisplatin arm. It is
possible that data from these randomized studies will confirm the value of docetaxel-based chemotherapy in
advanced gastric cancer and that docetaxel combinations will also be effective in the multidisciplinary efforts to
cure earlier stage cancer.
Introduction
Gastric carcinoma remains a major health problem in many
regions of the world. Incidence is extremely high in Oriental,
South American and Eastern European countries, but is also sig-
nificant in North America, Australia and Western Europe. Trends
in incidence and other aspects of the epidemiology of gastric
cancer are reviewed in detail elsewhere in this volume [1, 2].
Advanced gastric cancer remains incurable, and patients have a
median survival of 6–9 months. While chemotherapy can prolong
survival and improve quality of life when compared with best
supportive care alone, no one agent or combination regimen has
become accepted as the standard of treatment [1, 2]. Among the
single agents with proven activity in the first-line setting are
5-fluorouracil (5-FU), cisplatin, etoposide, irinotecan, mitomycin,
paclitaxel, S-1 and UFT (uracil/tegafur). With these agents,
response rates (RRs) ranging from 14% to 44% have been
reported. 5-FU, cisplatin, paclitaxel and irinotecan have also been
used as single agents second line, achieving RRs of 12% to 26%
[3–12].
Attempts to improve on these modest activities have taken a
variety of forms. In Italy, there was an attempt to intensify treat-
ment, using growth factor support, by adopting a weekly schedule.
In the ECF (epirubicin/cisplatin/5-FU) regimen, 5-FU is given by
protracted infusion, and this old drug has also been tried in novel
high-dose guises. However, there is also considerable interest in
the potential of relatively new cytotoxic agents, such as docetaxel.
This promising taxane has now been extensively assessed in
advanced gastric cancer. The data obtained with docetaxel as a
single agent and in combination are the focus of this paper.
Single-agent docetaxel
A series of phase II trials shows that docetaxel monotherapy has
appreciable activity in gastric cancer. In the second-line setting,
Vanhoefer et al. [13] achieved an RR of 20% in 25 evaluable
patients administered docetaxel 100 mg/m2. Also in second-line
patients, Taguchi et al. [14] administered docetaxel 60 mg/m2 and
reported a 22% RR in 45 evaluable cases. In previously untreated
patients, single-agent docetaxel has achieved RRs of 18%, 20%
and 24% when given at 100 mg/m2, and 18% when used at the
slightly lower dose of 75 mg/m2 [15–18]. The major single-agent
toxicity is hematological [19].
Docetaxel in combination with cisplatin: 
a European study
Prompted by these results, the Swiss Group for Clinical Cancer
Research (SAKK) and the European Institute for Oncology (EIO)
in Milan undertook to collaborate in studying the combination of
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docetaxel with cisplatin, which had already been extensively used
in gastric cancer.
In an initial phase II trial (n = 48), docetaxel 85 mg/m2 over
1–2 h was given together with cisplatin 75 mg/m2 over 4 h every
3 weeks for up to eight cycles. The RR by intention-to-treat was
52% in 48 patients, two of whom experienced a complete response
[20]. The median time to progression (TTP) was 6.6 months, and
the median overall survival time was 9 months. There were two
deaths, one a suicide.
Grade 3 [NCI Common Toxicity Criteria (CTC)] leucocyte
toxicity was seen in 40% of patients and grade 4 toxicity in 11%.
Grade 3 granulocyte toxicity was observed in 24% of patients and
grade 4 toxicity in 57%. This level of hematological toxicity was
expected and manageable: none of the nine episodes of febrile
neutropenia was fatal.
Other toxicities were relatively mild (Table 1). Grade 3 nausea
and vomiting was experienced in 1% of cycles, grade 3 fatigue
in 2%, grade 3 diarrhea in 2% and grade 3 mucositis in 2%.
The incidence of grade 3 neuropathy was 0.4%. No grade 4 non-
hematological toxicities were seen.
The SAKK-EIO experience with docetaxel/
cisplatin/5-FU
Having demonstrated the activity and tolerability of docetaxel/
cisplatin (TC), consideration was given to further developing the
doublet. When administered by continuous infusion, 5-FU is not
hematotoxic. Moreover, it could play a significant part in the
activity of the ECF regimen since, while 5-FU is given at 200 mg/m2
per day, the doses used of epirubicin (50 mg/m2) and cisplatin
(60 mg/m2) are modest. 5-FU therefore appeared to be a logical
choice for adding to TC, forming the triplet TCF (docetaxel/
cisplatin/5-FU).
In the dose escalation program used, the amount of cisplatin
administered was increased from an initial 60 mg/m2 (in dose
levels I and II) to 75 mg/m2 (at dose levels III–VIII), while that of
docetaxel increased in stages from 70 mg/m2 (at dose level I) to
85 mg/m2 (at dose levels II to VIII), and that of 5-FU from 200 mg/m2
(at dose levels I–III) to 225, 250, 275, 300 and 350 mg/m2 (at
dose levels IV, V,VI, VII and VIII, respectively) [21]. It proved
possible to maintain the docetaxel 85 mg/m2 and cisplatin 75 mg/m2
doses used in TC while adding 300 mg/m2 continuous infusion
5-FU on 2 weeks out of 3. The amount of hematoxicity observed
was little different from that seen with TC: grade 3 (NCI-CTC)
leucocyte toxicity was experienced by 44% and grade 4 toxicity
by 8% of patients; grade 3/4 granulocyte toxicity occurred in 27%/
54% of patients. Ten episodes of febrile neutropenia were seen
in nine patients. Full results regarding the safety profile and the
efficacy of the regimen are about to be submitted for publication.
TAX-325: a multinational phase II/III trial of 
TC versus TCF
In parallel with the SAKK-EIO initiative, a multinational effort
was mounted to conduct a randomized phase II comparison of TC
versus TCF [22]. The purpose of the study was to identify the
experimental arm to be taken forward into a phase III comparison
against cisplatin/5-FU. The independent Data and Safety Moni-
toring Committee charged with making this decision had access to
data on RR, TTP and safety as the trial progressed.
Design and patient characteristics
In TAX-325, 158 patients with advanced gastric cancer (99% of
them without prior chemotherapy) were randomized to receive
either docetaxel 85 mg/m2 plus cisplatin 75 mg/m2 every 3 weeks
(TC) or docetaxel 75 mg/m2 plus cisplatin 75 mg/m2 on day 1 plus
continuous infusion 5-FU 750 mg/m2 on days 1–5 every 3 weeks
(TCF) (Figure 1) [22]. Data are presented both for patients who
were treated per protocol, and for the entire intention-to-treat
population.
Table 2 shows that patient and disease characteristics were
reasonably well balanced across the two arms of the study. Those
involved were predominantly male, relatively young and had a
good performance status. All but 21% of patients had disease in
more than one organ, and in the majority of cases the liver and/or
peritoneum were involved. In a deliberate attempt to avoid the
possibly confounding effects of surgical intervention, the aim was
to avoid accruing patients with only localized disease. Hence, all
but 2% of the entire study population had metastatic disease.
Table 1. Non-hematological adverse events with 




Nausea/vomiting 29 12 1
Fatigue 40 21 2
Diarrhea 5 5 2
Mucositis 13 4 2
Neuropathy 14 8 0.4
Fluid retention 9 4 0
Anaphylactoid reaction 2 0 0.4
Table 2. TAX-325: characteristics of patients and disease treated with 





Male (%) 71 80
Median age (years) 55 54
Median performance status (%) 90 90
No prior chemotherapy (%) 99 99
No. of organs involved (%)
2 41 39
≥3 37 41
Metastatic disease (%) 100 98
Metastatic disease involving liver and/or 
peritoneum (%)
71 63
Bidimensionally measurable disease (%) 72 86
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The relative dose intensity across the study was uniformly high:
0.98 for docetaxel and 0.96 for cisplatin in the TC arm; and 0.93
for docetaxel, 0.92 for cisplatin and 0.92 for 5-FU in the TCF arm.
The doses stipulated for the trial therefore proved in practice to be
appropriate across the range of participating institutions.
Efficacy
Considering only those patients treated per protocol, the RR in the
TC arm was 32% (among 63 patients) and that in the TCF arm
54% (among 61 patients). By intention-to-treat analysis of the full
population, the RRs were 28% (in 76 patients) and 43% (in 79
patients), respectively. The difference between the two arms is
therefore maintained.
TCF was also superior in TTP, which was 5 months in the TC
arm and 5.9 months with TCF (intention-to-treat analysis). The
figures for overall survival showed a median of 10.5 months with
TC versus 9.6 months with TCF. It should be noted that this phase
II study was not powered to detect differences in overall survival
time as the end point. The objective of this phase II study was to
select the best combination for a phase III trial based on response
rate.
Toxicity
Toxicity, particularly of the gastrointestinal tract, was greater
with the TCF combination than with TC. Grade 3/4 (NCI-CTC)
stomatitis was seen in 9.6% of TCF cycles but in no TC cycle. The
corresponding figures for diarrhea were 4.6% and 1.2%, and for
nausea 4.8% and 3.2%. Where grade 3/4 stomatitis and diarrhea
occurred, the problem was usually evident in the first or second
cycle, and could be resolved by dose reduction.
Hematological toxicities were similar across the two arms of the
trial. Grade 3/4 neutropenia was seen in 62% of TC cycles and
52% of TCF cycles. However, the incidence of febrile neutropenia
was low (3% of TC cycles; 5% of TCF cycles), and there was one
treatment-related death in the TCF arm.
Based on the evidence of greater RR and longer TTP, and
despite greater gastrointestinal toxicity, the independent Data
Monitoring Committee elected the TCF regimen as the experi-
mental arm of the phase III portion of the trial. More than 300
patients have now been accrued, with a planned interim analysis
scheduled for summer 2002.
Discussion
The data reviewed above are derived from phase II studies (one of
which randomized patients to TC or TCF). They must therefore be
considered preliminary. However, there are two grounds for
hoping that the development of TC/TCF represents an advance.
First, there is consistency between the trials. Table 3 shows the
five published phase II studies that have investigated TC and TCF
regimens. Overall, the RRs range from 33% to 56%. TTPs, where
reported, range from 5 to 6.6 months, and median overall survival
time from 9 to 10.5 months. There is an impressive homogeneity
in these results [20–24].
Secondly, data from second-line studies show that docetaxel
can induce a response in patients who have already failed other
agents. Vanhoefer et al. [13] report a 20% RR in 25 patients
already exposed to first-line 5-FU and cisplatin (FUP). André et
Figure 1. TAX-325 phase II–III study design.
Table 3. Efficacy data from the five phase II studies of docetaxel/cisplatin 
(TC) and docetaxel/cisplatin/5-FU (TCF) in advanced gastric cancer [20–
24]
RR, response rate; TTP, time to progression.
Regimen [ref.] No. of 
patients




TC [20, 21] 48 56 6.6 9.0
TC [22] 63 35 5.0 9.6
TCF [22] 61 56 5.9 10.5
TC [23] 43 37 6.1 10.4
TC [24] 46 33 – 9.0
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al. [25] found a 21% RR when 25 patients pre-treated with FUP
were given epirubicin 75 mg/m2 plus docetaxel 75 mg/m2 every
3 weeks; and Giuliani et al. [26] reported a 17% RR with second-
line single-agent docetaxel 100 mg/m2. These data suggest that
using several agents up-front in a docetaxel-based combination
should have a substantial effect in chemotherapy-naive patients.
Nevertheless, data from randomized trials are required. To this
end, the SAKK-EIO group is collaborating with centers in the UK
on a phase II study in which patients are randomized to TC or TCF
or ECF. Whichever performs better out of the TC and TCF arms
will then move into a phase III comparison with ECF. This trial
will complement the ongoing international phase III comparison
of TCF against FUP.
A randomized trial of neoadjuvant TCF has also begun in the
hope that docetaxel-based combinations will be able to contribute
in the multidisciplinary effort to cure earlier stage disease.
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